Immuno Research Inc.

May 18, 2006 15:18 ET

Lakota Founder Joins Immuno Research Board of Directors

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - May 18, 2006) - Immuno Research Inc. (TSX VENTURE:IRI) is pleased to announce the appointment of Mr. Richard Stewart to the company's Board of Directors, effective immediately.

Mr. Stewart is the founder and CEO of Lakota Research International Inc., manufacturer of Canada's leading brand of topical pain relievers and herbal joint care supplements. He has 20 years of experience in developing, formulating, manufacturing, marketing and distributing pharmaceuticals and nutraceuticals to the human and veterinary markets.

Mr. Stewart initially began formulating products for racehorses while working as a trainer. It was his focus on the alleviation of joint, tendon and muscle pain in equine athletes that led to the formulation of the Lakota products for humans.

"Mr. Stewart's extensive background in the nutraceutical and pharmaceutical industries will have a direct influence on the successful development of Immuno's marketing and distribution systems and strategies," says John Mason, Immuno's president and CEO. "He has a proven track record of successfully introducing and promoting cutting-edge pharmaceuticals and supplements."

The company also announces it has issued 70,000 incentive stock options to an employee which are exercisable at a price of $0.50.

Finally, the company announces the resignation of Mr. Gary Saik from the Immuno Research Board of Directors. Immuno thanks Mr. Saik for his contributions during his tenure.

On behalf of the Board of Directors, John Mason, Chief Executive Officer

The Company seeks Safe Harbour.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • Ascenta Capital Partners Inc.
    Francis Reynolds
    Investor Relations
    (604) 684-4743 ext. 28 or Toll Free: 1-866-684-4743 ext. 28
    Immuno Research Inc.
    John Mason
    Vancouver Office
    (604) 807-8694
    (604) 926-1485 (FAX)